Fundação Pró-Rim, Joinville, SC, Brazil.
Universidade da Região de Joinville, Joinville, SC, Brazil.
J Bras Nefrol. 2024 Apr-Jun;46(2):e20230062. doi: 10.1590/2175-8239-JBN-2023-0062en.
The Brazilian Dialysis Survey (BDS) is an annual national survey about patients on chronic dialysis that contributes to health policies.
To report the 2022 epidemiological data from the BDS of the Brazilian Society of Nephrology (BSN).
A survey was carried out in Brazilian chronic dialysis centers using an online questionnaire that included clinical and epidemiological aspects of patients on chronic dialysis, dialysis therapy data, and dialysis center characteristics.
Overall, 28% (n = 243) of the centers answered the questionnaire. In July 2022, the estimated total number of patients on dialysis was 153,831. The estimated prevalence and incidence rates of patients per million population (pmp) were 758 and 214, respectively. Of the prevalent patients, 95.3% were on hemodialysis (HD, 4.6% of these on hemodiafiltration) and 4.7% on peritoneal dialysis (PD). Only 1.3% of patients were not vaccinated against COVID-19. The prevalence of anemia (Hb < 10g/dL) was 27% and hyperphosphatemia (P > 5.5mg/dL) reached 30%. The estimated overall crude annual mortality rate was 17.1%.
The absolute number and prevalence rate of patients on chronic dialysis continue to increase. A growing number of patients were receiving hemodiafiltration. The mortality rate decreased, probably due to the end of COVID-19 pandemic. The conclusions were drawn in the context of relatively low voluntary participation, which imposed methodological limitations on our estimates.
巴西透析调查(BDS)是一项针对慢性透析患者的年度全国性调查,为卫生政策提供了依据。
报告巴西肾病学会(BSN)的 2022 年 BDS 流行病学数据。
在巴西慢性透析中心进行了一项调查,使用在线问卷,其中包括慢性透析患者的临床和流行病学方面、透析治疗数据以及透析中心特征。
共有 28%(n=243)的中心回答了问卷。2022 年 7 月,估计接受透析的患者总数为 153831 人。每百万人口的估计患病率和发病率分别为 758 和 214。在现患患者中,95.3%接受血液透析(HD,其中 4.6%接受血液透析滤过),4.7%接受腹膜透析(PD)。只有 1.3%的患者未接种 COVID-19 疫苗。贫血(Hb<10g/dL)的患病率为 27%,高磷血症(P>5.5mg/dL)达到 30%。估计总的粗死亡率为 17.1%。
慢性透析患者的绝对数量和患病率继续增加。越来越多的患者接受血液透析滤过治疗。死亡率下降,可能是由于 COVID-19 大流行结束。由于自愿参与率相对较低,调查结论存在方法学上的局限性。